RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
=== 2000–2006 === The years from 2000 to 2006 were bloody ones in Colombia with thousands of deaths every year resulting from the ongoing war between the Colombian Armed Forces, Paramilitary groups such as the AUC, and the rebel groups (mainly the FARC, ELN and the EPL). The fighting resulted in massive internal displacement of Colombia's civilian population and thousands of civilian deaths. During President Uribe's first term in office (2002–2006), the security situation inside Colombia showed some measure of improvement, and the economy, while still fragile, showed some positive signs of recovery, according to observers. However, relatively little had been accomplished in structurally solving the country's other grave problems, such as poverty and inequality, possibly in part due to legislative and political conflicts between the administration and the Colombian Congress (including those over a controversial project to eventually give Uribe the possibility of re-election) and a relative lack of freely allocated funds and credits. Some critical observers considered that Uribe's policies, while reducing crime and guerrilla activity, were too slanted in favor of a military solution to Colombia's internal war, while neglecting grave social and human rights concerns. Critics asked for Uribe's government to change this position and make serious efforts towards improving the human rights situation inside the country, protecting civilians, and reducing any abuses committed by the armed forces.
=== Kidney === Regenerative capacity of the kidney has been recently explored. The basic functional and structural unit of the kidney is nephron, which is mainly composed of four components: the glomerulus, tubules, the collecting duct and peritubular capillaries. The regenerative capacity of the mammalian kidney is limited compared to that of lower vertebrates. In the mammalian kidney, the regeneration of the tubular component following an acute injury is well known. Recently regeneration of the glomerulus has also been documented. Following an acute injury, the proximal tubule is damaged more, and the injured epithelial cells slough off the basement membrane of the nephron. The surviving epithelial cells, however, undergo migration, dedifferentiation, proliferation, and redifferentiation to replenish the epithelial lining of the proximal tubule after injury. Recently, the presence and participation of kidney stem cells in the tubular regeneration has been shown. However, the concept of kidney stem cells is currently emerging. In addition to the surviving tubular epithelial cells and kidney stem cells, the bone marrow stem cells have also been shown to participate in regeneration of the proximal tubule, however, the mechanisms remain controversial. Studies examining the capacity of bone marrow stem cells to differentiate into renal cells are emerging. Like other organs, the kidney is also known to regenerate completely in lower vertebrates such as fish. Some of the known fish that show remarkable capacity of kidney regeneration are goldfish, skates, rays, and sharks.
== External links == "WISP wiki page". "Sensor Systems Lab WISP description". Archived from the original on 2018-10-11. Retrieved 2018-10-11. Alanson P. Sample; Daniel J Yeager; Pauline S Powledge; Alexander V Mamishev; Joshua R Smith (2018-06-06). "Design of an RFID-based battery-free programmable sensing platform". IEEE Transactions on Instrumentation and Measurement. 57 (11): 2608–2615. M. Segev-Bar; N. Bachar; Y.Wolf; B. Ukrainsky; L. Sarraf; H. Haick (Dec 13, 2016). "Multi‐Parametric Sensing Platforms Based on Nanoparticles". Advanced Materials Technologies. 2 (1) 1600206. doi:10.1002/admt.201600206. S2CID 63385571. [...] potentially to differentiate between the different signals. They have advantages in fields that include wearable systems, humanoid robotics, structural health monitoring and precision agriculture, [...]
The babies from this initial experiment were born in 1954, and the milestone was first publicized in the Cedar Rapids Gazette under the headline "Fatherhood After Death Has Now Been Proved Possible." After receiving his doctorate, Sherman accepted a position at the Biological Research Institute with the American Foundation for Biological Research in Madison, Wisconsin, in 1954. In 1957 Sherman joined the faculty at the University of Arkansas. He served as a professor there until 1992, when he became a professor emeritus and continued work until 1994. At University of Arkansas for Medical Sciences, he founded what is considered to be the second human semen cryobank. During his career, he also traveled by request to assist with the establishment of other cryobanks across the country. He also helped to establish and advocate for the Office of Minority Affairs within the School of Medical Sciences at Arkansas. From 1974 to 1975, he spent a year on sabbatical teaching at National Chung-Hsing University in Taichung, Taiwan. Throughout his career, Sherman was also active in professional societies including his role as a charter member of the Society of Cryobiology in 1964, where he also served on the society's editorial board; as a founder of the American Association of Tissue Banks, where he drafted the first standards for the cryobanking of human embryos; and as an advisor to the Food and Drug Administration on AIDS and cryobanking from 1988 to 1992.
Sources: en.wikipedia.org
=== In relation with experience === Thomas Nagel has said that "There are elements which, if added to one's experience, make life better; there are other elements which if added to one's experience, make life worse. But what remains when these are set aside is not merely neutral: it is emphatically positive." Experiences are central to a proposed dimension of well-being called psychological richness. This additional dimension of well-being was proposed as an empirically supported expansion to the hedonic vs. eudaimonic well-being dichotomy. Whereas hedonic well-being can be measured via life satisfaction, and eudaimonic well-being can be measured via one's perceptions of the meaning of their life, psychological richness is measured via characteristic experiences. Psychological richness is cultivated through having psychologically rich experiences, which are characterized as varying, interesting, novel, challenging, and perspective-changing, as subjectively measured by the experiencer. One line of evidence for this comes from studies conducted with college students, where students who went on trips (new and unusual experiences), whether they be short excursions or semester-length study abroad programs, reported increased psychological richness, but not increases in happiness or meaning (Oishi et al., 2021). In contrast to hedonic well-being, which is thought to result in personal satisfaction, and eudaimonic well-being, which is thought to result in societal contribution, psychological richness is thought to result in wisdom.
Mammals such as lemurs and monkeys demonstrate application of chemicals similar to how humans use chemicals for pest management and medical use. These applications vary from prevention of internal and external parasites or pathogens, decrease likelihood of infection, increase reproductive function, reducing inflammation, social cues, and more. Red-fronted lemurs (Eulemur ruffrons) have evolved two pathways, preventive measure for avoiding bioaccumulation, allowing for the modification of 2-methyl-1,4-benzoquinone and 2-methoxy-3-methyl-1,4-benzoquinone a secretion of Spirostreptidae millipedes shown to inhibit certain bacterial species. Red-fronted lemurs have also been observed in rubbing the secretion on their fur similar to capuchins, this action uses benzoquinone compounds as repellent for various insects such as ticks and mosquitoes.
Kamiyah as well as all the patients found through the column became the breakthrough needed to begin proper human research towards a diagnosis and treatment of the gene mutation. While Kamiyah was not able to technically receive a diagnosis for her illness, she created the pathway for research into possible treatments for patients in the future.
== Pre-Proto-Hassuna == More recently, the concept of a very early 'Pre-Proto-Hassuna' pottery tradition has been introduced by some scholars. This has been prompted by more recent discoveries of still earlier pottery traditions. Pre-Proto-Hassuna refers to the Late Neolithic period in Upper Mesopotamia when the ceramic containers were just being introduced. The pottery vessels were still very few in number in these early settlements. At that time, the main emphasis was on the pottery with a mineral temper, as opposed to the plant-tempered pottery which came to predominate later. The time frame for this period was about 7000-6700 BC, and at this time stone vessels and White Ware were still being used in addition to pottery. Because of the narrow local emphasis in many pottery studies as of now, these earliest pottery traditions may be known in literature as:
=== Macrophages === Oxidative burst in phagocytes is most commonly associated with bacterial killing. However, macrophages, especially alveolar macrophages, usually produce far lower levels of ROS than neutrophils, and may require activation for their bactericidal properties. Instead, their transient oxidative burst regulates the inflammatory response by inducing cytokine synthesis for redox signalling, resulting in an influx of neutrophils and activated macrophages.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.